drugset / Trial / NCT02651753

A Clinical Trial to Compare Safety and Pharmacokinetic Characteristics of CKD-337

NCT02651753

Phase 1 Completed 48 enrolled Chong Kun Dang Pharmaceutical
RandomizedCrossoverOpen-labelTreatment

Summary

This study is a randomized, open-label, single oral dose, 2-way crossover clinical trial to compare safety and pharmacokinetics of CKD-337 in healthy male volunteers.

Timeline

Start
2016-01
Primary completion
2016-03
Completion
2016-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Atorvastatin Small molecule 21.7 mg Oral
Subject CKD-337 Unknown 21.7 mg Oral
Subject CKD-337 Unknown 178.8 mg Oral
Subject Fenofibrate Small molecule 160 mg Oral

Indications